MCM
AMRX icon

MAI Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

MAI Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,831
Closed -$22.8K – 2206
2026
Q1 		$22.8K Buy
1,831
+80
+5% +$1.07K ﹤0.01% 2717
2025
Q4 		$22.1K Buy
1,751
+1
+0.1% +$11 ﹤0.01% 2462
2025
Q3 		$17.5K Hold
1,750
– – ﹤0.01% 2465
2025
Q2 		$14.2K Hold
1,750
– – ﹤0.01% 2539
2025
Q1 		$14.7K Sell
1,750
-250
-13% -$2.09K ﹤0.01% 2318
2024
Q4 		$15.8K Buy
+2,000
New +$16.8K ﹤0.01% 2321

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

MAI Capital Management's AMRX Position: Q2 2026 in Review

MAI Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 1,831 shares — an estimated $22.8K sold.

MAI Capital Management first reported a position in AMRX in Q4 2024 and held it in 6 quarters. The position peaked at $22.8K in Q1 2026. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • MAI Capital Management reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,831 Amneal Pharmaceuticals shares in Q2 2026, an estimated $22.8K.
  • MAI Capital Management first reported a position in Amneal Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Amneal Pharmaceuticals position peaked at $22.8K in Q1 2026.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.